

1 Cartilage Repair Using Hydrogels: A Critical Review of in Vivo 2 Experimental Designs

3 C. A. Vilela,^{†,‡,§,||} C. Correia,[#] J. M. Oliveira,^{†,‡} R. A. Sousa,[#] J. Espregueira-Mendes,^{†,‡,§,⊥}
4 and R. L. Reis^{*,†,‡,§}

5 [†]3B's Research Group, University of Minho, Guimarães, Portugal

6 [‡]ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal

7 [§]Life and Health Sciences Research Institute (ICVS), University of Minho, Braga, Portugal


8 ^{||}Orthopaedic Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal

9 [⊥]Clínica do Dragão, Espregueira-Mendes Sports Centre, Porto, Portugal

10 [#]Stemmatters, Biotecnologia e Medicina Regenerativa SA, Guimarães, Portugal

11 **ABSTRACT:** This review analyzes the outcomes and
12 technical aspects of in vivo studies published in the past
13 decade using gels and hydrogels for cartilage repair. Using
14 PubMed search engine, original research publications during
15 the period of 2002/01/01 to 2015/04/30 identified 115
16 published papers. Of these, 3 studies failed to find a statistically
17 significant improvement of treatment group as compared to
18 control and 18 studies did not clearly identify hyaline-like
19 cartilage formation in the treated groups. The most frequent
20 repaired lesion was the rabbit acute full thickness trochlear
21 defect, using a scaffold combining a gel or hydrogel and other
22 material. One third of the scaffolds were cell-free (35%) and
23 the majority of the studies did not use growth factors (71%).
24 The present review may constitute a useful tool in design of future studies, as limitations of study designs are pointed and results
25 in terms of translation to human application is discussed.

26 **KEYWORDS:** cartilage repair, hydrogels, gels, in vivo, animal, tissue engineering



1. INTRODUCTION

27 Articular cartilage has limited intrinsic capacity for self-repair,
28 because of the lack of vascular, neural, and lymphatic networks,
29 as well as absence of progenitor cells.^{1,2} According to Hjelle et
30 al, cartilage lesions were found in 60% of patients submitted to
31 knee arthroscopy.³ Cartilage lesions commonly progress to
32 osteoarthritis (OA), as a final state of disease evolution.^{2,4}
33 Presently, it is estimated that 10–15% of adults over 60 years
34 old show some symptoms of disease and by 2050, 130 million
35 people will suffer from osteoarthritis worldwide.⁵ The clinical
36 and economic impact is impressive, as the estimated direct and
37 indirect costs related to OA has surpassed \$65 billion annually.⁶
38 At earlier stages of cartilage damage, current therapies for
39 cartilage repair of lesions are not satisfactory as they fail to
40 restore a normal hyaline cartilage.^{7–9} Surgical approaches can
41 include microfracture, resurfacing techniques, and osteochon-
42 dral grafting.^{8–10} Autologous chondrocyte implantation (ACI)
43 and matrix-assisted autologous chondrocyte implantation
44 (MACI) are advanced approaches for regeneration of cartilage
45 lesions.^{9,10}

46 Microfracture and resurfacing techniques are easy to perform,
47 cost competitive, widely adopted, and well-documented
48 techniques that relieve symptomatic patients. However,

regenerated tissue is composed mostly by fibrocartilage, thus 49
providing short-term positive results in small cartilage 50
lesions.^{8,10} 51

Osteochondral grafting, the direct transplantation of an 52
osteochondral autograft (mosaicplasty) or allograft, is the only 53
technique available that satisfactorily restores hyaline cartilage.⁴ 54
However, donor site morbidity, risk of disease transmission, 55
possible graft-versus-host immune response (in the case of 56
allografts) and osteoarthritic exacerbation can occur due to lack 57
of congruency between treated and untreated surfaces, thus 58
limiting the use of those techniques.⁴ 59

On the other hand, ACI and MACI are expensive techniques, 60
which demand complex protocols and two different surgeries. 61
Promising results have been reported,⁴ but poor consistence of 62
clinical outcomes with time, cells and/or cartilage fragment 63
loosening, arthrofibrosis, osteophytes development, synovitis, 64
infection and chondromalacia have been described.^{4,10} 65

Many of the limitations of current available treatments justify 66
the quest for more effective approaches and development of 67

Received: June 6, 2015

Accepted: August 13, 2015




Figure 1. Number of original scientific publications per year published between 2002 and 2014 reporting in vivo experiments on cartilage repair according to animal model.

68 new biomaterials for cartilage repair. Interestingly, hydrogels
69 have attracted great deal of attention because of its performance
70 characteristics, i.e., are soft, of synthetic or natural origin, and
71 can form three-dimensional networks that can be tuned for its
72 biocompatibility, bioadhesiveness, and biodegradability.^{11,12}

73 Hydrogels present other advantageous features for tissue
74 engineering applications,^{11–14} such as extracellular matrix
75 mimetic; swelling ability while maintaining shape; capability
76 to undergo volume phase or sol–gel phase transitions in
77 response to physical and/or chemical stimuli; tunable surface
78 and bulk properties to modulate cells adhesion and
79 thrombogenicity; support to high diffusion kinetics of nutrients
80 and metabolic products within the construct.

81 There are several chemical or physical cross-linking
82 techniques, photopolymerization, or even microfabrication
83 technologies,^{13,15,16} which can optimize hydrogel physicochem-
84 ical characteristics and biological behavior,¹³ and improve
85 performance of hydrogels in cartilage tissue engineering
86 strategies. Furthermore, hydrogels can be combined with
87 other materials improving its properties.^{17–19}

88 The application of hydrogels as volume fillers and cell
89 carriers can contribute significantly to the development of more
90 effective regeneration strategies²⁰ in irregular shape cartilage
91 defects. Additionally, the opportunity to treat such lesions by a
92 single step procedure using simpler surgical protocols, in which
93 an injectable solution is delivered by a minimally invasive
94 procedure, can minimize significantly treatment cost, improve
95 patient safety and comfort, and support treatment in an
96 outpatient setting.

97 This review compiles in vivo studies reporting the use of
98 hydrogels for repairing cartilage lesions and analyzes its
99 performance in different animal models. A thorough analysis
100 of experimental variables was further performed, constituting a
101 useful tool for researchers when designing future in vivo studies
102 for cartilage repair.

2. METHODS

103 **2.1. Keyword-Based Search.** Original research publications were
104 identified by the use of PubMed search engine, during the period
105 comprised between 2002/01/01 and 2015/04/30, and using the
106 following keywords: “cartilage”, “osteochondral”, “cartilage repair”,
107 “tissue engineering”, “scaffold”, “cells”, “gel”, “gels”, “hydrogel”, and
108 “hydrogels”, using AND/OR Boolean operators. The terms such as

“eye”, “heart”, “tooth”, “skin”, “root”, “dermal”, “dentin”, “cardiovas-
109 cular”, “hepatic”, “gastric”, “gastrointestinal”, and “biochemistry” were
110 excluded.

111 **2.2. Inclusion/Exclusion Selection.** All abstracts were evaluated
112 by four independent reviewers based on the following inclusion
113 criteria: English language, and experimental protocol reporting in vivo
114 use of hydrogels in repair of cartilage defects. The following exclusion
115 criteria were applied: Other language rather than English; in vitro studies;
116 studies not involving use of hydrogels; studies reporting use of
117 hydrogels in other application contexts or studies in which the
118 hydrogel could not be considered as a scaffold. Whenever the abstract
119 was unclear or insufficient for determination of its inclusion/exclusion,
120 the Materials and Methods section and/or the complete publication
121 were analyzed before a decision was made.

122 **2.3. Evaluation and Final Selection.** After selection of abstracts,
123 a second evaluation was carried out, during which all publications were
124 analyzed and discussed among the four reviewers in order to produce
125 the final list of publications to be overviewed.

126 **2.4. Full Text Review.** All included articles were submitted to a
127 full-text review. For each paper, the respective list of references was
128 verified to identify possible relevant studies that might have been
129 undetected through PubMed-based search.

3. RESULTS

130 **3.1. Publication Selection and Review.** Keyword based
131 search identified a total of 14295 publications. After inclusion/
132 exclusion selection, 902 papers related to study of articular
133 cartilage repair have been identified. Then, evaluation and final
134 selection of those papers, according to defined inclusion and
135 exclusion criteria, identified a total of 93 papers. During the
136 selection process, 809 studies have been excluded due to several
137 reasons, such as in vitro experimental protocol, experiments not
138 aimed at repairing cartilage defects, or papers reporting clinical
139 investigations. For each paper, the list of references was verified,
140 which allowed identification of 22 additional publications.
141 Herein, the total number of published original articles
142 identified, reviewed and included was 115.

143 **3.2. Distribution of Publications Per Year.** The
144 distribution of publications per year is shown in Figure 1.
145 Between 2002 and 2010, the number of publications reporting
146 in vivo experiments concerning cartilage repair have increased
147 every year. After 2010, the number of publications per year
148 appears to have stabilized between 10 and 13 papers per year.
149

150 **3.3. Animal Models.** Upon analysis of the publications,
151 several outcomes were obtained regarding animal models and
152

152 respective experimental protocol (Figure 2). According to
153 Figure 2A, the rabbit model was the most common for studying




Figure 2. Distribution of animal models, characterization of the induced defect and lesion treatment and bioactive agents used: (A) animal model; (B) lesion type; (C) location of the lesion; (D) techniques for defect induction; (E) disease stage; (F) type of scaffold; (G) type of cells: adipose mesenchymal stem cells (aMSC), muscle mesenchymal stem cells (mMSC), synovium mesenchymal stem cells (sMSC), bone-marrow mesenchymal stem cells (bmMSC) and human mesenchymal stem cells (hMSC); (H) growth factors: transforming growth factor (TGF), bone morphogenetic protein (BMP), fibroblast growth factor (FGF), platelet-rich plasma (PRP).

154 cartilage repair by means of using hydrogels, comprising 73.3%
155 of all studies. Noticeably, other animal models selected for
156 evaluation of hydrogel performance included large animals,
157 such as goat and sheep models, representing 3.1 and 5.3% of all
158 studies, respectively (Figure 2A). Minipigs were the second
159 animal more frequently used comprising 9.9% of all studies
160 (Figure 2A).

161 **3.3.1. Age and Weight of Animals.** Table 1 summarizes the
162 data regarding age and weight of animals for all the studies
163 analyzed. The absolute ranges depend very much on the animal
164 model. The animal model with the wider age interval was the

sheep, with a relative interval of 40–260 weeks. As concerns
weight, the animal models with wider weight intervals were
sheep and horse, with a relative interval of 22.5 to 80 kg and
307 to 439 kg, respectively.

3.3.2. Number of Animals Per Study. Table 2 presents the
number of animals used for each study and the time interval for
the time points according to each animal model. The most
common number of animals used per study was 12, as this was
the mode obtained for mini-pig, rabbit, and sheep models. As
for the duration of the studies, 12 weeks was the mode obtained
for the most used animal models, rabbit and mini-pig, yet
ranging from 4 and 8 to 52 weeks, respectively.

3.4. Experimental Protocol. **3.4.1. Type and Geometry of**
Defects. From Figure 2, it is possible to state that the most
frequently induced cartilage defect was a full thickness lesion
(80%, Figure 2B), done in the trochlea (63%, Figure 2C) by
drilling (67%, Figure 2D) and treated at an acute stage (95%,
Figure 2E).

Cartilage defect dimensions were also thoroughly analyzed,
including area, depth, and volume (Table 3). Most defects had
a circular shape, yet 8 articles reported a rectangular or square
shape.^{21–28} Therefore, for comparison purposes, it was adopted
the defect area to characterize surface dimension. Dimensions
varied according to the animal model employed. In general,
dimensions of induced cartilage defect were proportional to the
size of the animal. For rat, the minimum area of the lesion was
0.6 mm² and for horse the maximum area was 176.7 mm². For
rabbit, the most frequently adopted animal model, the mode of
the lesion area was 7.1 mm², whereas the lesion area varied
between 1.8 and 200 mm². The very large variation in defect
area results from one study where the defect included the
complete excision of tibial plateau.²⁹

3.4.2. Type of Scaffold. From Figure 2F, it is evident that
“combined materials” prevail as the most frequent type of
scaffold (51%). These are composed by two or more materials
of either of natural or of synthetic origin. The other types of
scaffolds that has been mostly investigated were natural derived
scaffolds (39%) and synthetic scaffolds (10%).

When analyzing use of scaffolds with cells, about 65% of all
studies analyzed involved the use of cells, in a so-called
combination repair strategy. Nevertheless, about 35% of
cartilage lesions where treated with hydrogels alone (Figure
3A).

3.4.3. Type of Cells. For combination approaches where
scaffolds are combined with cells, 27% of studies used
chondrocytes, whereas 38% used mesenchymal stem cells
(Figure 2G). A thorough description of cell types and
concentrations used in the analyzed studies are displayed in
Table 4. Chondrocytes were the most widely used cell type in a
concentration range between 5.00×10^4 and 5.00×10^7 cells/
mL, followed by mesenchymal stem cells (MSC) that have
been used in a range between 1.50×10^5 and 7.20×10^5 cells/
mL. We noticed that 35% of the scaffolds were cell-free.

3.4.4. Bioactive Agents. Besides the use of cells with the
hydrogels in combination strategies to repair cartilage lesions,
growth factors have been also explored to improve quality of
regenerated tissue. According to Figure 2H, published papers
used at least one growth factor (29%) for repair of cartilage
lesions. Transforming growth factor (TGF) was the most
frequent choice, accounting for 11% of studies, whereas bone
morphogenetic protein (BMP) and fibroblast growth factor
(FGF) were each used in 3 and 2% of all studies, respectively.
Insulin growth factor (IGF), growth differentiation factor 227

Table 1. Maximum, Minimum, Average, and Mode of Age and Weight of Animals Used for in Vivo Experiments on Cartilage Repair According to Animal Model As Reported in Analyzed Publications^a

Animal	Age (Weeks)				Weight (Kg)			
	Max	Min	Avg	Mode	Max	Min	Avg	Mode
dog ^b			104.0				9.4	
goat					47.6	23.9	33.8	
horse	182	156	169.0		439.0	307.0	373.0	
mini pig	156	16	43.2	24/32/44	42.0	11.0	26.2	36.5
monkey ^b			312.0				8.0	
rabbit	96	8	20.8	24	4.7	1.8	3.1	2.3/3.3
rat	12	5	10.7	12	0.4	0.3	0.3	
sheep	260	40	152.4	117	80.0	22.5	64.9	68.0/80.0

^aAbbreviations: max, maximum; min, minimum; avg, average. ^bOnly 1 study with this animal model.

Table 2. – Maximum, Minimum, Average, and Mode of the Number of Animals and Duration of Study Adopted for in Vivo Experiments on Cartilage Repair According to Animal Model As Reported in Analyzed Publications^a

animal	no. of animals/paper				duration (weeks)			
	max	min	avg	mode	max	min	avg	mode
dog ^b			9.0				10.0	
goat	20	4	12.5		24	12	19.0	24
horse	6	6	6.0		32	24	28.0	
mini pig	27	6	14.8	12/16/18/20	52	8	20.0	1
monkey ^b			16.0				24.0	
rabbit	81	3	27.3	12	52	4	13.9	12
rat	121	9	40.2		12	4	7.0	
sheep	24	3	11.4	10/12	52	3	27.0	16/52

^aAbbreviations: max, maximum; min, minimum; avg, average. ^bOnly 1 study with this animal model.

Table 3. Maximum, Minimum, Average, and Mode of the Number of Lesions, Lesion Area, Lesion Depth, and Lesion Volume Adopted for in Vivo Experiments on Cartilage Repair According to Animal Model As Reported in Analyzed Publications^a

animal	no. of lesions				lesion area (mm ²)				lesion depth (mm)				lesion volume (mm ³)			
	max	min	avg	mode	max	min	avg	mode	max	min	avg	mode	max	min	avg	mode
dog ^b			2.0				19.6				4.5				88.4	
goat	2	2	2.0	2	28.3	19.6	24.0		4.0	3.0	3.3	3.0	113.1	58.9	78.9	58.9
horse	2	2	2.0		176.7	176.7	176.7		2.8	2.8	2.8		486.0	486.0	486.0	
mini pig	8	1	2.8	2	56.7	12.6	32.3	28.3	6.0	1.0	2.6	1.0/3.0	169.6	28.3	87.1	28.3
monkey ^b			2.0				7.1				5.0				35.3	
rabbit	6	1	2.1	2	200.0	1.8	15.4	7.1	15.0	0.5	3.7	3.0	217.8	3.5	51.0	21.2
rat	2	1	1.5	1	3.1	0.6	1.9	1.8	2.0	1.0	1.5		6.3	1.8	3.3	
sheep	12	1	5.0	4	50.3	8.0	32.4	28.3/38.5	12.0	2.0	6.7	12.0	423.1	32.2	205.5	77.0/339.3

^aAbbreviations: max, maximum; min, minimum; avg, average. ^bOnly 1 study with this animal model.

(GDF), connective tissue growth factor (CTGF), and Nel-like molecule-1 (NELL-1) account for a total of 3% of studies (Figure 2H). Noticeably, platelet-rich plasma (PRP) has also considerable expression in this context, accounting for 2% of all studies (Figure 2H).

3.4.5. Time Points and Study Groups. Table 5 presents number of time points, number of study groups, and number of lesions per study group for the analyzed publications. Concerning the number of time points, the majority of studies included at least 2 time points, yet the number ranged from 1 time point up to 7 time points. Three study groups was the most common among all animal models, yet the number of lesions per study group averaged 12–15.4, for the mini-pig and rabbit models, respectively.

For all animal models, the number of study groups was between 2 and 9. Concerning the number of lesions by study group (N), this index was calculated according the equation:

$$N = \frac{\text{no. of animals} \times \text{no. of lesions by animal}}{\text{no. of study groups}}$$

According to Table 5, the number of lesions per study groups was between 3 and 74.0.

3.4.6. Characterization of Cartilage Repair. Several techniques have been used to evaluate regeneration of cartilage tissue within the induced lesions. Histological staining of cartilage explants were done in all studies, including hematoxylin and eosin staining in most of the studies, complemented with at least one of the following: alcian blue, toluidine blue, safranin O, and/or Masson's trichrome staining. Immunohistochemistry staining, commonly used for identification of collagen type II and/or collagen type I, were done in 71 reports. For histological evaluation several histological scores were chosen: O'Driscoll, Pineda, ICRS, Mankin, Moran, Wakitani, Wayne, Sellefs, Caplan, and Susante. In 15 papers, two of the previous scores were used simultaneously. O'Driscoll




Figure 3. Correlation of data variables. (A) Inner circle: distribution of scaffold type used in each animal model; outer circle: efficacy of each scaffold type in forming hyaline cartilage. Lateral column displays overall efficacy of the animal model in yielding hyaline cartilage outcomes, further discriminated by scaffold type. (B1) Inner circle: distribution of cell ± growth factors used in each scaffold type; outer circle: efficacy of each cell ± growth factor combination in forming hyaline cartilage. Lateral column displays overall efficacy of scaffold type in yielding hyaline cartilage outcomes, further discriminated by cell ± growth factor combination. (B2) Inner circle: distribution of lesion area used in each scaffold type; outer circle: efficacy of lesion area in yielding hyaline cartilage outcomes. (B3) Inner circle: distribution of lesion type used in each scaffold type; outer circle: efficacy of lesion type in yielding hyaline cartilage outcomes.

Table 4. Maximum, Minimum, and Average Number of Cells Used for in Vivo Experiments on Cartilage Repair According to Cell Type and Animal Model As Reported in Analyzed Publications^a

cell type	cell concentration (cells/mL)	animal							
		dog ^b	goat	horse	mini pig	monkey ^b	rabbit	rat	sheep
aMsc	max						1.50 × 10 ⁰⁷	1.00 × 10 ⁰⁶	
	min						1.00 × 10 ⁰⁶	1.00 × 10 ⁰⁶	
	avg						9.00 × 10 ⁰⁶	1.00 × 10 ⁰⁶	
bMsc	max		5.00 × 10 ⁰⁷		7.00 × 10 ⁰⁶	1.00 × 10 ⁰⁶	5.00 × 10 ⁰⁷		7.20 × 10 ⁰⁵
	min		5.00 × 10 ⁰⁷		1.00 × 10 ⁰⁵	1.00 × 10 ⁰⁶	1.50 × 10 ⁰⁵		4.00 × 10 ⁰⁵
	avg	1.00 × 10 ⁰⁷	5.00 × 10 ⁰⁷		2.28 × 10 ⁰⁶	1.00 × 10 ⁰⁶	1.28 × 10 ⁰⁷		5.07 × 10 ⁰⁵
BNC	max				1.00 × 10 ⁰⁵				
	min				1.00 × 10 ⁰⁵				
	avg				1.00 × 10 ⁰⁵				
chondrocytes	max		5.00 × 10 ⁰⁶		5.00 × 10 ⁰⁷		5.00 × 10 ⁰⁷	5.00 × 10 ⁰⁴	4.00 × 10 ⁰⁷
	min		1.00 × 10 ⁰⁶		2.00 × 10 ⁰⁵		7.50 × 10 ⁰⁴	5.00 × 10 ⁰⁴	1.00 × 10 ⁰⁶
	avg	-	3.00 × 10 ⁰⁶	1.20 × 10 ⁰⁷	1.59 × 10 ⁰⁷		5.76 × 10 ⁰⁶	5.00 × 10 ⁰⁴	1.63 × 10 ⁰⁷
HMsc	max						1.00 × 10 ⁰⁶	2.00 × 10 ⁰⁷	
	min						1.00 × 10 ⁰⁶	2.00 × 10 ⁰⁷	
	avg						1.00 × 10 ⁰⁶	2.00 × 10 ⁰⁷	
mMsc	max						2.00 × 10 ⁰⁶		
	min						1.00 × 10 ⁰⁶		
	avg						1.50 × 10 ⁰⁶		
PBC	max						2.36 × 10 ⁰⁷		
	min						2.36 × 10 ⁰⁷		
	avg						2.36 × 10 ⁰⁷		
periosteal cells	max								8.00 × 10 ⁰⁶
	min								8.00 × 10 ⁰⁶
	avg								8.00 × 10 ⁰⁶
sMsc	max						1.00 × 10 ⁰⁸		
	min						1.00 × 10 ⁰⁶		
	avg						3.82 × 10 ⁰⁷		

^aaMSC: adipose mesenchymal stem cells; bmMSC: bone-marrow mesenchymal stem cells; bmNC: bone-marrow nucleated cells; HMSC: human mesenchymal stem cells; mMsc: muscle mesenchymal stem cells; PBC: peripheral blood mononuclear cells; sMSC: synovium mesenchymal stem cells; max, maximum; min, minimum; avg, average. ^bOnly 1 study with this animal model.

Table 5. Maximum, Minimum, Average, and Mode of the Number of Time Points, Number of Study Groups, and Number of Lesions Per Study Group Adopted for in Vivo Experiments on Cartilage Repair According to Animal Model As Reported in Analyzed Publications

animal	no. of time points				no. of study groups				no. of lesions/study group		
	max	min	avg	mode	max	min	avg	mode	max	min	avg
dog ^a			2.0				2.0		9	9	9.0
goat	3	1	2.0	2	4	2	3.0	3	12	3	8.3
horse	2	1	1.5		2	2	2.0		6	6	6.0
mini pig	3	1	1.5	1	5	2	3.1	3	24	5	12.0
monkey ^a			3.0				2.0				16.0
rabbit	7	1	2.3	2	9	2	3.3	3	74	3	15.4
rat	3	1	1.8	1	7	3	3.9	3	20	13	16.8
sheep	3	1	1.7	1/2	6	2	3.9	4	20	6	10.8

^aOnly 1 study with this animal model.

scoring was used, alone or combined with another score, in 29 publications, followed by Wakitani scoring in 20 studies and by the ICRS scoring in 19 papers. In 32 studies, no histological score was used to evaluate the quality of cartilage regeneration. As outcome of histological evaluation, most studies have obtained statistically significant improvement in cartilage regeneration for treated groups as compared to control groups. In 3 papers,^{30–32} no significant histological improvement was observed between treated and untreated groups, and in 4

papers,^{33–36} no histological differences were found between study groups. Most studies reported on the development of hyaline-like cartilage, while 8 studies^{37–44} reported no cartilage like tissue or a mixture of fibrous cartilage and hyaline-like cartilage in the repaired tissue. In 14 studies,^{23,30–32,45–51} the repair tissue was not classified as hyaline-like cartilage. In 5 papers,^{21,52–54} a tendency for deterioration of cartilage tissue along time was reported.

277 Quantitatively, gene expression was evaluated in 25 studies
278 (21,7%). Characterization of mechanical performance of
279 regenerated tissue was highly uncommon, as it was performed
280 in 8 studies. Imaging evaluation including magnetic resonance
281 imaging (MRI), microcomputed tomography (μ -CT), laser
282 scanning arthroscopy, and optical coherence tomography
283 (OCT) was performed in 19 studies.

284 **3.4.7. Side Effects.** Several side effects have been reported in
285 the studies analyzed such as inflammation, degeneration, tissue
286 hypertrophy, among others. No information was given related
287 to this issue in 26 studies. Inflammatory response was reported
288 in 9 studies,^{24,31,52,55–60} including, synovitis, fibrosis, and
289 fissures. By its turn, 13 papers reported degenerative or
290 pathological changes like osteophytes, cyst formation, or bone
291 hypertrophy. In these studies, one of the following were used: a
292 periosteal flap in a chondrocyte cell-laden scaffold,²¹ PRPs,⁶¹ a
293 growth factor (TGF β ,^{62,63} BMP-2,³¹ FGF⁵²), or cells (ASC,⁶⁴
294 BMSC,⁶⁵ MSC,^{25,54} chondrocytes⁶⁶ chondrocytes/periosteal
295 cells⁶⁷). In another study,⁶⁸ the control group developed a
296 degenerative change.

4. DISCUSSION

297 The present systematic review revealed that hydrogels used for
298 cartilage repair include those composed by single natural or
299 synthetic biomaterials, or by combination of these, designated
300 as “combined materials” (Figure 2F). Advantages/disadvan-
301 tages of natural and synthetic biomaterials for cartilage repair
302 are detailed elsewhere.^{69,70} Among the literature revised, 39% of
303 studies proposed natural materials including colla-
304 gen,^{21,22,25,26,28,32,39,47,50,52,58,63,64,71–76} algi-
305 nate,^{37,38,40,48,62,77–80} fibrin,^{29,33,81,82} platelet-rich plasma,^{61,83}
306 hyaluronic acid,^{27,31,57,84,85} gellan gum,⁸⁶ chitosan,^{42,87} and
307 sugar cane biopolymer.⁸⁸ For 10% of studies, synthetic
308 materials included oligo(poly(ethylene glycol) fumarate)
309 (OPF),^{43,46,89} poly(*N*-isopropylacrylamide-*co*-acrylic acid)
310 (poly(NiPAAm-*co*-AAc)),⁹⁰ poly(L-lactide-*co*-3-caprolactone)
311 (PLCL),^{91,92} Si-HPMC,³⁶ polypeptides,^{35,65,93} and α -CD-EG
312 4400.⁹⁴ The scaffolds using combined materials were composed
313 by two or more natural materials, representing 51% of the
314 studies,^{17–19,49,60,66–68,95–100} by association of two or more
315 synthetic polymers,^{101–109} by the association of natural
316 materials with a synthetic polymer,^{20,23,44,45,51,54–56,59,76,110–128}
317 128 by association of others materials.^{24,30,34,41,53,129–132} When

318 analyzing Table 6, it is clear that most biomaterials succeed (to
319 a higher or less extent) on regenerating hyaline matrix, while
320 delivering bioactive agents such as cells and/or growth factors,
321 as well as fulfilling fundamental requirements for translation
322 into human scenario. Major limitations of these gels/hydrogels
323 relate to unsatisfactory mechanical properties, capable to
324 immediately withstand load after treatment, as well as a
325 mismatch of biomaterial degradation rate as compared to tissue
326 regeneration (either too fast or to slow). The combination of
327 the hydrogel with a rigid scaffold has been tested (for example
328 PLCL,²³ PLA/PLGA,⁹² aiming to improve mechanical proper-
329 ties, whereas the downside relates to loss of injectability, and
330 consequently, adequacy of the system to be delivered by a
331 minimally invasive approach. Cross-linking mechanisms differ
332 among the biomaterial types, yet can be used, to a certain
333 extent, to fine-tune mechanical properties as well as degradation
334 rate of the hydrogels. Not less important in the cartilage repair
335 equation, is the capacity to mimic the complex layered structure
336 of articular cartilage tissue. Although current gels and hydrogels
337 are still limited in this regard, future developments in the

Table 6. Characteristics of the Biomaterials Used As Gels/Hydrogels for Cartilage Repair^a

	injectability	delivery of bioactive agents	adverse immune response	cellular recognition	pathogen transmission	cross-linking	mechanical properties	degradation	integration with native tissue	hyaline cartilage	ref
NATURAL											
collagen	+	+	+	+	+	+	+	+	+	+	21,22,25,26,28,32,39,47,50,52,58,63,64,69–74
alginate	+	+	+	+	+	+	+	+	+	+	37,38,40,48,62,75–78
fibrin	+	+	+	+	+	+	+	+	+	+	29,33,79,80
platelet-rich plasma	+	+	+	+	+	+	+	+	+	+	61,81
hyaluronic acid	+	+	+	+	+	+	+	+	+	+	27,31,57,82,83
gellan gum	+	+	+	+	+	+	+	+	+	+	84
chitosan	+	+	+	+	+	+	+	+	+	+	42,85
oligo(poly(ethylene glycol) fumarate)	+	+	+	+	+	+	+	+	+	+	43,46,87
poly(<i>N</i> -isopropylacrylamide- <i>co</i> -acrylic acid)	+	+	+	+	+	+	+	+	+	+	88
silanized hydroxypropyl methylcellulose	+	+	+	+	+	+	+	+	+	+	36
polypeptides	+	+	+	+	+	+	+	+	+	+	35,65,91

^aLabel: + : positive for cartilage repair; –: negative for cartilage repair; /: lack of information.

biomaterials field might pursue this target, by providing more sophisticated, smart, and multifunctional materials for improved cartilage regeneration.^{133,134}

Regarding the animal model used, the rabbit was the preferred, comprising 73.3% of all studies. Rabbits gather several features that make it an attractive model for cartilage regeneration research. It is of easy handling, caging, and care, has a good cost effectiveness and enough dimensions of the trochlear groove and condyles for the induction of a 3–4 mm diameter cartilage defects.¹³⁵ However, the relatively thin cartilage thickness (approximately 0.4 ± 0.1 mm in the trochlear groove),¹³⁶ has limited the volume size of the cartilage defect.¹³⁵ Another limitation of this animal model is the high degree of the rabbit knee flexion, creating a partial weight-bearing condition when the trochlear groove is chosen as location for cartilage defect induction/repair.¹³⁷ The present review revealed that the majority of studies used were immature rabbits younger than 8 months, the minimum age considered for maturity of rabbits.¹³⁸ The above-mentioned disadvantages and the high potential of the rabbit model for spontaneous healing,^{84,139} especially in immature animals, are important limitations to address when the rabbit is used as a translational model to human knee cartilage. Herein, it was noticed a progressive use of larger and more weighted animal models, allowing bigger cartilage defects that reproduce better the size, depth, and conditions of human cartilage lesions.¹³⁵ Furthermore, some of these models, as opposed to rabbit, have a low spontaneous cartilage repair ability,^{140–142} and similar to humans, suffer from osteochondritis dissecans and osteoarthritis pathologies.¹³⁵

An articular cartilage defect is classified as full or partial-thickness defect according to the penetration into the subchondral bone.^{116,143} Considering the known cartilage thickness of the different animal models,^{135,144} the majority of the defects overviewed in this review are deeper than the expected cartilage thickness for those models, therefore, these were classified as full-thickness defects or as osteochondral defect. This is a very important drawback regarding the relevance of the models used for evaluation of cartilage repair performance, given that in humans superficial cartilage lesions are the most common, and only 5% are osteochondral defects.³

Most of the studies have reported the treatment of cartilage defects at an acute stage. From the total publications analyzed, only 6 were related to chronic stages of the cartilage defect.^{34,63,64,75,111,113} It is recognized that a chronic cartilage lesion is a diverse condition as compared to an acute cartilage lesion.^{26,34,145} This fact highlights the importance of addressing the correct stage of lesion progression in animal models when translating to human treatment.

As for tissue characterization, the majority of the studies included immunohistochemical evaluation of the neo-cartilage by evaluating the presence of collagen type I and type II, whereas expression of type X was determined in only 3 studies.^{19,115,132} It is important to identify the expression of collagen type X, in order to exclude the possibility of hypertrophic tissue development or a transient cartilage.⁶⁴

Determination of gene expression was performed in 24 studies. In these, an increase in cartilage-related gene expression was found in the regenerated tissue. Nevertheless, given the mismatch of information regarding gene expression, it is not possible to perform a full comparison between studies.

Assessment of mechanical performance of the new tissue is a relevant dimension when evaluating quality of the cartilage

repair. Yet, its implementation is difficult, as it depends on anatomical location, measurement methodology and specific conditions of the joint.⁶⁶ The mechanical properties of the repaired tissue were evaluated in only 8 studies. In most of these, properties of the new tissue were similar or close to native cartilage.^{24,32,34,77,114} Some authors found inconsistent results⁷⁵ and repaired tissue showed a higher stiffness as compared to normal cartilage.^{24,94} As expected, similar mechanical properties between repaired tissue and normal cartilage was correlated with regenerated hyaline-like cartilage, except for the study by Pulkkinen et al.,³² which despite mechanical properties being similar to native cartilage, the repaired tissue did not correspond histologically to hyaline-like cartilage. From these studies, two main issues can be highlighted: (i) large variety of reported methodologies among studies for determining mechanical performance of regenerated cartilage; (ii) adopted methodologies that do not reflect natural physiological condition.⁶⁶ These issues pose additional challenges when assessing quality of the regenerated cartilage in animal models using new biomaterial/therapeutic candidates, and when translating such performance during proof-of-concept or preclinical setting, to human performance in clinical setting.

The majority of the studies did not compare the treatment groups with reference treatments, adopted as clinical standard, such as microfracture or osteochondral grafting, which would be of high value to infer the relative efficacy of the new biomaterial/therapeutic candidates. For full-thickness defects (the most frequent defect type studied), the nontreated control group acts in a similar way to microfracture as there is exposure to bone marrow. Yet, for partial-thickness defect, only 1 study compared the outcome with microfracture treatment.⁸⁶ Concerning osteochondral grafting, only 2 studies compared the results of between scaffold treated groups with osteochondral grafting.^{34,48}

Regarding the use of cells, most studies used chondrocytes, although mesenchymal stem cells (MSC) have been also highly explored.³⁹ Adipose mesenchymal stem cells (aMSC), muscle mesenchymal stem cells (mMSC), synovium mesenchymal stem cells (sMSC), and bone-marrow mesenchymal stem cells (bmMSC) were used, which avoid donor site morbidity in the cartilage tissue. Among the different stem cell sources, it was stated that sMSC and bmMSC show a greater chondrogenic potential as compared to aMSC or mMSC, while one study reported, in addition, greater proliferation potential of sMSC.²⁸ Many researchers have reported an improvement in bone and cartilage formation^{39,59} when MSC were implanted. These improvements were promising, with a superior cartilage bonding to adjacent native cartilage, when compared with articular chondrocytes.⁶⁴ However, some authors^{44,50,54,121} did not find better results in cartilage regeneration when MSCs were used.

Regarding the the use of growth factors, a relationship between use of growth factors and inflammatory response or pathological changes, was not found. However, reported responses were identified in only 5 experiments that have used growth factors.^{24,31,62,63,65} For 1 case using BMP-2, extensive ectopic bone formation was observed.³¹

TGF- β seems to be dose-dependent and lower concentrations are more effective in repairing cartilage defects and decrease osteophyte formation.⁶² TGF- β 1 has been suggested to have a pro-inflammatory response, but no study using TGF- β 1 reported an inflammatory response. TGF- β 1 promoted

464 trabecular bone subchondral appearance but did not improve
465 cartilage cell morphology or glycosaminoglycan (GAG)
466 expression,⁴⁴ while TGF- β 3 was suggested to have a chemo-
467 tactic cue for cell homing.¹¹⁴ The combination of BMP-7 and
468 TGF- β 1 was found to induce chondrogenic differentiation.¹¹⁵

469 To be considered mature hyaline cartilage, the repaired tissue
470 must exhibit normal morphology of chondrocytes and normal
471 safranin O staining and possess an adequate structural
472 organization with vertical columnar alignment of chondrocytes.
473 When the last condition is not attained, the repair tissue is
474 classified as immature. If the tissue is composed of dense
475 spindle-shaped fibroblasts, the tissue is graded as fibrous tissue.
476 When the repair tissue contains cells beginning to differentiate
477 toward chondrocytes, the tissue is called as undifferentiated
478 mesenchymal tissue.^{48,146} Another important aspect is that 3
479 studies did not obtain statistically significant improvement in
480 treated groups when compared with untreated group.^{30–32}

481 Although the majority of studies reported improvement of
482 cartilage regeneration in treated groups, 22 studies did not
483 recognize formation of hyaline-like cartilage at the repaired
484 defect site. Therefore, better scoring of repaired tissue does not
485 mean necessarily hyaline-like cartilage formation. Further
486 discussion might focus on reliability and adequacy of scores
487 used to evaluate regenerated cartilage tissue. Bonasia et al,
488 tested the inter- and intraobserver reliability of 10 scores and
489 concluded that, for evaluation of cartilage repair in animal
490 models, the ICRS II, O'Driscoll and modified O'Driscoll scores
491 are preferential given their high reliability, and the fact that the
492 whole joint is available for histological assessment.¹⁴⁷ On the
493 other hand, for evaluation of human cartilage biopsies, the
494 ICRS I or II or Oswestry score are preferable given the limited
495 tissue available.¹⁴⁷

496 The studies analyzed herein evaluated repaired tissue mostly
497 by the O'Driscoll score, followed by the Wakitani. One of the
498 limitations of these scores relate to the lack of validation by
499 biochemical analysis.¹⁴⁸ Only the Bern score has undergone
500 such validation, yet has been considered more adequate for
501 analysis of tissue-engineered constructs¹⁴⁸ instead of repair of
502 cartilage in animal models. Accordingly, it was not used in any
503 of the revised studies. For the O' Driscoll score, safranin O
504 staining grading is not reflected in the final score and a limited
505 difference was observed between a "moderate" and a "poor"
506 quality of regenerated cartilage.¹⁴⁸ Although the O' Driscoll
507 score includes evaluation of repaired tissue structure, it does
508 not consider other parameters such as mineral degeneration,
509 vascularity, subchondral bone, viability cell population,
510 inflammation, and cartilage plug quality.¹⁴⁸ As previously
511 reported,¹⁴⁹ evaluation of cartilage repair should make use of
512 more than one score, complemented by biochemical,
513 automated histomorphometry, and biomechanical correlation.

514 **Data Correlation.** Given the above-mentioned compilation
515 of data, one would be tempted to understand which
516 combination of factors would seem the most promising in
517 yielding regeneration of cartilage tissue. Despite the high
518 number of variables and possible combinations, an excel VBA
519 application was developed in order to correlate data. Studies
520 were characterized as "hyaline" or "no hyaline" based on the
521 studies' author classification of repaired tissue. Subsequently,
522 studies were selected based on the use or no use of cells (C)
523 and/or growth factors (GF), by animal model or lesion size,
524 ultimately correlated by type of scaffold (natural, synthetic, or
525 combined materials). Outcomes are displayed in Figure 3.

Regarding the animal model (Figure 3A), despite the rabbit 526
not being recommended as a model to evaluate cartilage repair 527
due to small cartilage thickness, and high spontaneous 528
regeneration,^{150,151} when analyzing Figure 3A, it is evident 529
that among all animal models, the rabbit has been the most 530
widely used, comprising 73.3% of all studies. Of these, 62.9% 531
claimed to have generated hyaline-like cartilage tissue. 532
Apparently, combined scaffolds were responsible for such 533
outcome, comprising 41.2% of the hyaline repaired tissue. 534
Nevertheless, for bigger animal models (goat, sheep, and mini 535
pig), the natural origin scaffolds seem to result in superior 536
hyaline-like cartilage regeneration, as compared to those using 537
combined or synthetic hydrogels. 538

When analyzing from another perspective, it was possible to 539
determine that 55.6% of all rabbit studies used combined 540
scaffolds, and these generated 65.6% of all hyaline-positive 541
outcomes. This trend is maintained for all animal models, 542
whereas the synthetic scaffolds seem to yield inferior outcomes. 543

Figure 3B1 displays an analysis of the combination of cells 544
(C) and/or growth factors (GF) with the different types of 545
hydrogels, and their synergistic effect on cartilage repair. In fact, 546
of all studies analyzed, 51.5% used hydrogels composed of 547
combined materials and resulted in a 70.6% success rate on 548
generating hyaline-like cartilage. Those using scaffolds of 549
natural origin (38.6%) seem less successful, where only 45.1% 550
generated hyaline regeneration. Nevertheless, it does seem that 551
the presence of cells generally improve probability of successful 552
regeneration of tissue, as major percentage of successful 553
outcomes where achieved through the use of cells in 554
combination with the scaffold, while the positive effect of the 555
presence of growth factors is not so evident (Figure 3B1). 556

An additional correlation factor was lesion size, where type of 557
scaffold (natural, synthetic or combined), was related to the 558
lesion area (<3 mm², 3–6 mm², or >6 mm²) and relative 559
percentage of incidence on generating hyaline cartilage was 560
analyzed (Figure 3B2). Overall, hydrogels of combined 561
materials seem to perform better than natural or synthetic 562
hydrogels, in nearly all dimension ranges, yet it seems that for 563
larger lesions, natural origin hydrogels provided better 564
outcomes. 565

On what regards deepness of lesion (Figure 3B3), full- 566
thickness was the most used and the most successful in 567
obtaining hyaline cartilage, according to their authors. 568
However, interpretation of this outcome is limited to the 569
reduced number of studies that have tested repair of partial 570
lesions (only 5% of all studies). 571

Study Limitations Acknowledged by Authors. Some 572
authors pointed several limitations in their studies: the 573
dimension of the sample^{27,30,34,39,67,103,43,108} and specific 574
problems with design of the study.^{44,65,96,101,102} In addition, 575
several limitations have been pointed out, such as lack of 576
biomechanical evaluation,^{28,67,99,104–106,112,129,131} short follow- 577
up,^{27,43,62,77,101,103,105,106,109,113,122,130,131} animal immaturity, 578
and type of animal model,^{77,104,105,110,117} poor representative- 579
ness of human pathology,⁹³ origin-cell identification not 580
possible in the majority of the studies,^{25,26,67,131} absence of a 581
specific rehabilitation program,¹¹³ and experimentation under 582
no load bearing conditions.^{34,106} The International Cartilage 583
Repair Society (ICRS)¹⁵⁰ and the American Society for Testing 584
and Materials (ASTM)¹⁵¹ have published guidelines and 585
recommendations for preclinical studies aiming cartilage repair, 586
that could be considered by researchers in order to generate 587
valuable and comparable data, ultimately contributing to 588

589 stronger advancement of knowledge in the field of cartilage
590 repair.

5. CONCLUSIONS

591 In summary, hydrogel biomaterials seem to be promising
592 candidates for cartilage repair, given that hyaline-like cartilage
593 development was proved in a considerable number of studies. A
594 potential advantage of using hydrogels for cartilage repair is its
595 suitability for arthroscopic delivery, yet, in many studies,
596 hydrogel properties did not seem compatible with this
597 minimally invasive approach. Overall, further development on
598 surgical technique will be required.

599 The majority of the published papers addressed small, acute
600 and a full-thickness cartilage defect in a nonweight bearing area.
601 These conditions are very different from those found in human
602 patients which is a concerning limitation considering translation
603 of experimental learnings toward human treatment. The need
604 for animal models and experimental designs that consider those
605 aspects is obvious and must be considered in future animal
606 experimentation studies.

607 In addition, anticipation of potential therapeutic efficacy in
608 human demands a more conclusive mechanical evaluation of
609 the regenerated tissue, as well as long-term studies. Not less
610 important is the need of standardization of the evaluation
611 procedures, especially on what concerns histology in order to
612 enable comparison among different studies. The use of uniform
613 guidelines for the definition of the general conditions and
614 techniques to be used in cartilage repair experiments is
615 mandatory to ensure comparability of studies.

AUTHOR INFORMATION

Corresponding Author

618 *E-mail: rgreis@dep.uminho.pt.

Notes

620 The authors declare no competing financial interest.

ACKNOWLEDGMENTS

622 This work was supported by the ARTICULATE project
623 (QREN-13/SI/2011-23189).

REFERENCES

- 625 (1) Buckwalter, J. A. Articular cartilage: injuries and potential for
626 healing. *J. Orthop Sports Phys. Ther* **1998**, *28* (4), 192–202.
- 627 (2) Hunziker, E. B. Articular cartilage repair: are the intrinsic
628 biological constraints undermining this process insuperable? *Osteo-*
629 *arthritis Cartilage* **1999**, *7* (1), 15–28.
- 630 (3) Hjelle, K.; Solheim, E.; Strand, T.; Muri, R.; Brittberg, M.
631 Articular cartilage defects in 1,000 knee arthroscopies. *Arthroscopy*
632 **2002**, *18* (7), 730–4.
- 633 (4) Hunziker, E. B. Articular cartilage repair: basic science and clinical
634 progress. A review of the current status and prospects. *Osteoarthritis*
635 *Cartilage* **2002**, *10* (6), 432–63.
- 636 (5) Tanna, S. Background Paper 6.12 Osteoarthritis. In *Priority*
637 *Medicines for Europe and the World “A Public Health Approach to*
638 *Innovation”*, Wittenauer, R., Smith, L., Aden, K., Eds.; World Health
639 Organization: Geneva, Switzerland, 2013.
- 640 (6) Jackson, D. W.; Simon, T. M.; Aberman, H. M. Symptomatic
641 articular cartilage degeneration: the impact in the new millennium.
642 *Clin. Orthop. Relat. Res.* **2001**, *391 Suppl*, S14–25.
- 643 (7) Tins, B. J.; McCall, I. W.; Takahashi, T.; Cassar-Pullicino, V.;
644 Roberts, S.; Ashton, B.; Richardson, J. Autologous chondrocyte
645 implantation in knee joint: MR imaging and histologic features at 1-
646 year follow-up. *Radiology* **2005**, *234* (2), 501–8.

- (8) Gobbi, A.; Nunag, P.; Malinowski, K. Treatment of full thickness
chondral lesions of the knee with microfracture in a group of athletes. *647*
Knee Surg Sports Traumatol Arthrosc **2005**, *13* (3), 213–21. *648*
649
- (9) Luyten, F. P.; Vanlauwe, J. Tissue engineering approaches for
osteoarthritis. *Bone* **2012**, *51* (2), 289–96. *650*
651
- (10) Brittberg, M.; Lindahl, A.; Nilsson, A.; Ohlsson, C.; Isaksson, *652*
O.; Peterson, L. Treatment of deep cartilage defects in the knee with
autologous chondrocyte transplantation. *N. Engl. J. Med.* **1994**, *331* *653*
654
655
- (11) Cabral, J.; Moratti, S. C. Hydrogels for biomedical applications. *656*
Future Med. Chem. **2011**, *3* (15), 1877–88. *657*
- (12) Baroli, B. Hydrogels for tissue engineering and delivery of *658*
tissue-inducing substances. *J. Pharm. Sci.* **2007**, *96* (9), 2197–223. *659*
- (13) Gauvin, R.; Parenteau-Bareil, R.; Dokmeci, M. R.; Merryman, *660*
W. D.; Khademhosseini, A. Hydrogels and microtechnologies for
engineering the cellular microenvironment. *Wiley Interdiscip Rev.* *661*
Nanomed Nanobiotechnol **2012**, *4* (3), 235–46. *662*
663
- (14) Oliveira, J. T.; Reis, R. L. Polysaccharide-based materials for *664*
cartilage tissue engineering applications. *J. Tissue Eng. Regen. Med.* *665*
2011, *5* (6), 421–36. *666*
- (15) Khademhosseini, A.; Langer, R.; Borenstein, J.; Vacanti, J. P. *667*
Microscale technologies for tissue engineering and biology. *Proc. Natl.* *668*
Acad. Sci. U. S. A. **2006**, *103* (8), 2480–7. *669*
- (16) Khademhosseini, A.; Langer, R. Microengineered hydrogels for *670*
tissue engineering. *Biomaterials* **2007**, *28* (34), 5087–92. *671*
- (17) Filova, E.; Jelinek, F.; Handl, M.; Lytvynets, A.; Rampichova, *672*
M.; Varga, F.; Cinatl, J.; Soukup, T.; Trc, T.; Amler, E. Novel
composite hyaluronan/type I collagen/fibrin scaffold enhances repair *673*
of osteochondral defect in rabbit knee. *J. Biomed. Mater. Res., Part B* *674*
2008, *87* (2), 415–424. *675*
676
- (18) Pei, M.; He, F.; Boyce, B. M.; Kish, V. L. Repair of full-thickness *677*
femoral condyle cartilage defects using allogeneic synovial cell-
engineered tissue constructs. *Osteoarthritis Cartilage* **2009**, *17* (6), *678*
679
680
- (19) Siu, R. K.; Zara, J. N.; Hou, Y.; James, A. W.; Kwak, J.; Zhang, *681*
X.; Ting, K.; Wu, B. M.; Soo, C.; Lee, M. NELL-1 promotes cartilage
regeneration in an in vivo rabbit model. *Tissue Eng., Part A* **2012**, *18* *682*
683
684
- (20) Wang, W.; Li, B.; Yang, J.; Xin, L.; Li, Y.; Yin, H.; Qi, Y.; Jiang, *685*
Y.; Ouyang, H.; Gao, C. The restoration of full-thickness cartilage
defects with BMSCs and TGF-beta 1 loaded PLGA/fibrin gel *686*
constructs. *Biomaterials* **2010**, *31* (34), 8964–73. *687*
688
- (21) Adachi, N.; Sato, K.; Usas, A.; Fu, F. H.; Ochi, M.; Han, C. W.; *689*
Niyibizi, C.; Huard, J. Muscle derived, cell based ex vivo gene therapy
for treatment of full thickness articular cartilage defects. *J. Rheumatol.* *690*
2002, *29* (9), 1920–1930. *691*
692
- (22) Han, C. W.; Chu, C. R.; Adachi, N.; Usas, A.; Fu, F. H.; Huard, *693*
J.; Pan, Y. Analysis of rabbit articular cartilage repair after chondrocyte
implantation using optical coherence tomography. *Osteoarthritis* *694*
Cartilage **2003**, *11* (2), 111–21. *695*
696
- (23) Cohen, S. B.; Meirisch, C. M.; Wilson, H. A.; Diduch, D. R. The *697*
use of absorbable co-polymer pads with alginate and cells for articular
cartilage repair in rabbits. *Biomaterials* **2003**, *24* (15), 2653–2660. *698*
699
- (24) Fukuda, A.; Kato, K.; Hasegawa, M.; Hirata, H.; Sudo, A.; *700*
Okazaki, K.; Tsuta, K.; Shikunami, Y.; Uchida, A. Enhanced repair of
large osteochondral defects using a combination of artificial cartilage *701*
and basic fibroblast growth factor. *Biomaterials* **2005**, *26* (20), 4301–8. *702*
703
- (25) Yanai, T.; Ishii, T.; Chang, F.; Ochiai, N. Repair of large full-
thickness articular cartilage defects in the rabbit: the effects of joint *704*
distraction and autologous bone-marrow-derived mesenchymal cell
transplantation. *J. Bone Jt. Surg., Br. Vol.* **2005**, *87* (5), 721–9. *705*
706
707
- (26) Lee, J. H.; Prakash, K. V.; Pengatteei, Y. H.; Park, S. E.; Koh, H. *708*
S.; Han, C. W. Chondrocyte apoptosis in the regenerated articular
cartilage after allogenic chondrocyte transplantation in the rabbit knee. *709*
J. Bone Jt. Surg., Br. Vol. **2007**, *89* (7), 977–983. *710*
711
- (27) Kang, S. W.; Bada, L. P.; Kang, C. S.; Lee, J. S.; Kim, C. H.; *712*
Park, J. H.; Kim, B. S. Articular cartilage regeneration with
microfracture and hyaluronic acid. *Biotechnol. Lett.* **2008**, *30* (3), *713*
714
715

- 716 (28) Koga, H.; Muneta, T.; Nagase, T.; Nimura, A.; Ju, Y. J.;
717 Mochizuki, T.; Sekiya, I. Comparison of mesenchymal tissues-derived
718 stem cells for in vivo chondrogenesis: suitable conditions for cell
719 therapy of cartilage defects in rabbit. *Cell Tissue Res.* **2008**, *333* (2),
720 207–15.
- 721 (29) Chang, F.; Ishii, T.; Yanai, T.; Mishima, H.; Akaogi, H.; Ogawa,
722 T.; Ochiai, N. Repair of large full-thickness articular cartilage defects
723 by transplantation of autologous uncultured bone-marrow-derived
724 mononuclear cells. *J. Orthop. Res.* **2008**, *26* (1), 18–26.
- 725 (30) Aulin, C.; Bergman, K.; Jensen-Waern, M.; Hedenqvist, P.;
726 Hilborn, J.; Engstrand, T. In situ cross-linkable hyaluronan hydrogel
727 enhances chondrogenesis. *J. Tissue Eng. Regen. Med.* **2011**, *5* (8),
728 e188–96.
- 729 (31) Aulin, C.; Jensen-Waern, M.; Ekman, S.; Hagglund, M.;
730 Engstrand, T.; Hilborn, J.; Hedenqvist, P. Cartilage repair of
731 experimentally 11 induced osteochondral defects in New Zealand
732 White rabbits. *Lab. Anim.* **2013**, *47* (1), 58–65.
- 733 (32) Pulkkinen, H. J.; Tiitu, V.; Valonen, P.; Jurvelin, J. S.; Rieppo, L.;
734 Toyras, J.; Silvast, T. S.; Lammi, M. J.; Kiviranta, I. Repair of
735 osteochondral defects with recombinant human type II collagen gel
736 and autologous chondrocytes in rabbit. *Osteoarthritis Cartilage* **2013**,
737 *21* (3), 481–90.
- 738 (33) Wilke, M. M.; Nydam, D. V.; Nixon, A. J. Enhanced early
739 chondrogenesis in articular defects following arthroscopic mesen-
740 chymal stem cell implantation in an equine model. *J. Orthop. Res.*
741 **2007**, *25* (7), 913–25.
- 742 (34) Marquass, B.; Somerson, J. S.; Hepp, P.; Aigner, T.; Schwan, S.;
743 Bader, A.; Josten, C.; Zscharnack, M.; Schulz, R. M. A novel MSC-
744 seeded triphasic construct for the repair of osteochondral defects. *J.*
745 *Orthop. Res.* **2010**, *28* (12), 1586–99.
- 746 (35) Shah, R. N.; Shah, N. A.; Del Rosario Lim, M. M.; Hsieh, C.;
747 Nuber, G.; Stupp, S. I. Supramolecular design of self-assembling
748 nanofibers for cartilage regeneration. *Proc. Natl. Acad. Sci. U. S. A.*
749 **2010**, *107* (8), 3293–8.
- 750 (36) Portron, S.; Merceron, C.; Gauthier, O.; Lesoeur, J.; Sourice, S.;
751 Masson, M.; Fellah, B. H.; Geffroy, O.; Lallemand, E.; Weiss, P.;
752 Guicheux, J.; Vinatier, C. Effects of in vitro low oxygen tension
753 preconditioning of adipose stromal cells on their in vivo chondrogenic
754 potential: application in cartilage tissue repair. *PLoS One* **2013**, *8* (4),
755 e62368.
- 756 (37) Madry, H.; Cucchiari, M.; Stein, U.; Remberger, K.; Menger,
757 M. D.; Kohn, D.; Trippel, S. B. Sustained transgene expression in
758 cartilage defects in vivo after transplantation of articular chondrocytes
759 modified by lipid-mediated gene transfer in a gel suspension delivery
760 system. *J. Gene Med.* **2003**, *5* (6), 502–9.
- 761 (38) Mierisch, C. M.; Wilson, H. A.; Turner, M. A.; Milbrandt, T. A.;
762 Berthou, L.; Hammarskjold, M. L.; Rekosh, D.; Balian, G.; Diduch, D.
763 R. Chondrocyte transplantation into articular cartilage defects with use
764 of calcium alginate: the fate of the cells. *J. Bone Jt. Surg. Am.* **2003**, *85*
765 (9), 1757–1767.
- 766 (39) Chang, C. H.; Kuo, T. F.; Lin, F. H.; Wang, J. H.; Hsu, Y. M.;
767 Huang, H. T.; Loo, S. T.; Fang, H. W.; Liu, H. C.; Wang, W. C. Tissue
768 engineering-based cartilage repair with mesenchymal stem cells in a
769 porcine model. *J. Orthop. Res.* **2011**, *29* (12), 1874–80.
- 770 (40) Heiligenstein, S.; Cucchiari, M.; Laschke, M. W.; Bohle, R. M.;
771 Kohn, D.; Menger, M. D.; Madry, H. In vitro and in vivo
772 characterization of nonbiomedical- and biomedical-grade alginates
773 for articular chondrocyte transplantation. *Tissue Eng., Part C* **2011**, *17*
774 (8), 829–42.
- 775 (41) Filova, E.; Rampichova, M.; Litvinec, A.; Drzik, M.; Mickova, A.;
776 Buzgo, M.; Kostakova, E.; Martinova, L.; Usvald, D.; Prosecka, E.;
777 Uhlík, J.; Motlik, J.; Vajner, L.; Amler, E. A cell-free nanofiber
778 composite scaffold regenerated osteochondral defects in miniature
779 pigs. *Int. J. Pharm.* **2013**, *447* (1–2), 139–49.
- 780 (42) Martins, E. A.; Michelacci, Y. M.; Baccarin, R. Y.; Cogliati, B.;
781 Silva, L. C. Evaluation of chitosan-GP hydrogel biocompatibility in
782 osteochondral defects: an experimental approach. *BMC Vet. Res.* **2014**,
783 *10* (1), 197.
- (43) Hui, J. H.; Ren, X.; Afizah, M. H.; Chian, K. S.; Mikos, A. G. 784
Oligo[poly(ethylene glycol)fumarate] hydrogel enhances osteochon- 785
dral repair in porcine femoral condyle defects. *Clin. Orthop. Relat. Res.* 786
2013, *471* (4), 1174–85. 787
- (44) Guo, X.; Park, H.; Young, S.; Kretlow, J. D.; van den Beucken, J. 788
J.; Baggett, L. S.; Tabata, Y.; Kasper, F. K.; Mikos, A. G.; Jansen, J. A. 789
Repair of osteochondral defects with biodegradable hydrogel 790
composites encapsulating marrow mesenchymal stem cells in a rabbit 791
model. *Acta Biomater.* **2010**, *6* (1), 39–47. 792
- (45) Ferretti, M.; Marra, K. G.; Kobayashi, K.; Defail, A. J.; Chu, C. 793
R. Controlled in vivo degradation of genipin crosslinked polyethylene 794
glycol hydrogels within osteochondral defects. *Tissue Eng.* **2006**, *12* 795
(9), 2657–63. 796
- (46) Holland, T. A.; Bodde, E. W.; Cuijpers, V. M.; Baggett, L. S.; 797
Tabata, Y.; Mikos, A. G.; Jansen, J. A. Degradable hydrogel scaffolds 798
for in vivo delivery of single and dual growth factors in cartilage repair. 799
Osteoarthritis Cartilage **2007**, *15* (2), 187–97. 800
- (47) Mimura, T.; Imai, S.; Kubo, M.; Isoya, E.; Ando, K.; Okumura, 801
N.; Matsusue, Y. A novel exogenous concentration-gradient collagen 802
scaffold augments full-thickness articular cartilage repair. *Osteoarthritis* 803
Cartilage **2008**, *16* (9), 1083–91. 804
- (48) Sun, J.; Hou, X. K.; Li, X.; Tang, T. T.; Zhang, R. M.; Kuang, Y.; 805
Shi, M. Mosaicism associated with gene enhanced tissue engineering 806
for the treatment of acute osteochondral defects in a goat model. *Arch* 807
Orthop Trauma Surg **2009**, *129* (6), 757–71. 808
- (49) Rampichova, M.; Filova, E.; Varga, F.; Lytvynets, A.; Prosecka, 809
E.; Kolacna, L.; Motlik, J.; Necas, A.; Vajner, L.; Uhlík, J.; Amler, E. 810
Fibrin/hyaluronic acid composite hydrogels as appropriate scaffolds 811
for in vivo artificial cartilage implantation. *ASAIO J.* **2010**, *56* (6), 812
563–8. 813
- (50) Yamazoe, K.; Mishima, H.; Torigoe, K.; Iijima, H.; Watanabe, 814
K.; Sakai, H.; Kudo, T. Effects of atelocollagen gel containing bone 815
marrow-derived stromal cells on repair of osteochondral defect in a 816
dog. *J. Vet. Med. Sci.* **2007**, *69* (8), 835–9. 817
- (51) Zheng, Y.; Lv, H.; Wang, Y.; Lu, H.; Qing, L.; Xi, T. 818
Performance of novel bioactive hybrid hydrogels in vitro and in vivo 819
used for artificial cartilage. *Biomed. Mater.* **2009**, *4* (1), 015015. 820
- (52) Tanaka, H.; Mizokami, H.; Shiigi, E.; Murata, H.; Ogasa, H.; 821
Mine, T.; Kawai, S. Effects of basic fibroblast growth factor on the 822
repair of large osteochondral defects of articular cartilage in rabbits: 823
dose-response effects and long-term outcomes. *Tissue Eng.* **2004**, *10* 824
(3–4), 633–41. 825
- (53) Tanaka, T.; Komaki, H.; Chazono, M.; Fujii, K. Use of a 826
biphasic graft constructed with chondrocytes overlying a beta- 827
tricalcium phosphate block in the treatment of rabbit osteochondral 828
defects. *Tissue Eng.* **2005**, *11* (1–2), 331–9. 829
- (54) Shao, X. X.; Huttmacher, D. W.; Ho, S. T.; Goh, J. C.; Lee, E. H. 830
Evaluation of a hybrid scaffold/cell construct in repair of high-load- 831
bearing osteochondral defects in rabbits. *Biomaterials* **2006**, *27* (7), 832
1071–80. 833
- (55) Kim, K.; Lam, J.; Lu, S.; Spicer, P. P.; Lueckgen, A.; Tabata, Y.; 834
Wong, M. E.; Jansen, J. A.; Mikos, A. G.; Kasper, F. K. Osteochondral 835
tissue regeneration using a bilayered composite hydrogel with 836
modulating dual growth factor release kinetics in a rabbit model. *J.* 837
Controlled Release **2013**, *168* (2), 166–78. 838
- (56) Qi, B. W.; Yu, A. X.; Zhu, S. B.; Zhou, M.; Wu, G. Chitosan/ 839
poly(vinyl alcohol) hydrogel combined with Ad-hTGF-beta1 trans- 840
fected mesenchymal stem cells to repair rabbit articular cartilage 841
defects. *Exp. Biol. Med. (London, U. K.)* **2013**, *238* (1), 23. 842
- (57) Lee, K. B.; Hui, J. H.; Song, I. C.; Ardany, L.; Lee, E. H. 843
Injectable mesenchymal stem cell therapy for large cartilage defects—a 844
porcine model. *Stem Cells* **2007**, *25* (11), 2964–71. 845
- (58) Zhang, Y.; Wang, F.; Chen, J.; Ning, Z.; Yang, L. Bone marrow 846
derived mesenchymal stem cells versus bone marrow nucleated cells in 847
the treatment of chondral defects. *Int. Orthop.* **2012**, *36* (5), 1079–86. 848
- (59) Wang, W.; Li, B.; Li, Y.; Jiang, Y.; Ouyang, H.; Gao, C. In vivo 849
restoration of full-thickness cartilage defects by poly(lactide-co- 850
glycolide) sponges filled with fibrin gel, bone marrow mesenchymal 851
stem cells and DNA complexes. *Biomaterials* **2010**, *31* (23), 5953–65. 852

- 853 (60) Filova, E.; Rampichova, M.; Handl, M.; Lytvynets, A.; Halouzka, 922
854 R.; Usvald, D.; Hlucilova, J.; Prochazka, R.; Dezortova, M.; Rolencova, 923
855 E.; Kostakova, E.; Trc, T.; Stastny, E.; Kolacna, L.; Hajek, M.; Motlik, 924
856 J.; Amler, E. Composite hyaluronate-type I collagen-fibrin scaffold in 925
857 the therapy of osteochondral defects in miniature pigs. *Physiol. Res.* 926
858 **2007**, *56* (Suppl 1), S5–S16.
- 859 (61) Kuo, T. F.; Lin, M. F.; Lin, Y. H.; Lin, Y. C.; Su, R. J.; Lin, H. 927
860 W.; Chan, W. P. Implantation of platelet-rich fibrin and cartilage 928
861 granules facilitates cartilage repair in the injured rabbit knee: 929
862 preliminary report. *Clinics (Sao Paulo)* **2011**, *66* (10), 1835–8.
- 863 (62) Mierisch, C. M.; Cohen, S. B.; Jordan, L. C.; Robertson, P. G.; 930
864 Balian, G.; Diduch, D. R. Transforming growth factor-beta in calcium 931
865 alginate beads for the treatment of articular cartilage defects in the 932
866 rabbit. *Arthroscopy* **2002**, *18* (8), 892–900.
- 867 (63) Zscharnack, M.; Hepp, P.; Richter, R.; Aigner, T.; Schulz, R.; 933
868 Somerson, J.; Josten, C.; Bader, A.; Marquass, B. Repair of chronic 934
869 osteochondral defects using predifferentiated mesenchymal stem cells 935
870 in an ovine model. *Am. J. Sports Med.* **2010**, *38* (9), 1857–69.
- 871 (64) Marquass, B.; Schulz, R.; Hepp, P.; Zscharnack, M.; Aigner, T.; 936
872 Schmidt, S.; Stein, F.; Richter, R.; Osterhoff, G.; Aust, G.; Josten, C.; 937
873 Bader, A. Matrix-associated implantation of predifferentiated mesen- 938
874 chymal stem cells versus articular chondrocytes: in vivo results of 939
875 cartilage repair after 1 year. *Am. J. Sports Med.* **2011**, *39* (7), 1401–12.
- 876 (65) Miller, R. E.; Grodzinsky, A. J.; Vanderploeg, E. J.; Lee, C.; 940
877 Ferris, D. J.; Barrett, M. F.; Kisiday, J. D.; Frisbie, D. D. Effect of self- 941
878 assembling peptide, chondrogenic factors, and bone marrow-derived 942
879 stromal cells on osteochondral repair. *Osteoarthritis Cartilage* **2010**, *18* 943
880 (12), 1608–19.
- 881 (66) Chiang, H.; Kuo, T. F.; Tsai, C. C.; Lin, M. C.; She, B. R.; 944
882 Huang, Y. Y.; Lee, H. S.; Shieh, C. S.; Chen, M. H.; Ramshaw, J. A.; 945
883 Werkmeister, J. A.; Tuan, R. S.; Jiang, C. C. Repair of porcine articular 946
884 cartilage defect with autologous chondrocyte transplantation. *J. Orthop.* 947
885 *Res.* **2005**, *23* (3), 584–93.
- 886 (67) Schagemann, J. C.; Erggelet, C.; Chung, H. W.; Lahm, A.; Kurz, 948
887 H.; Mrosek, E. H. Cell-laden and cell-free biopolymer hydrogel for the 949
888 treatment of osteochondral defects in a sheep model. *Tissue Eng, Part* 950
889 *A* **2009**, *15* (1), 75–82.
- 890 (68) Liu, Y.; Shu, X. Z.; Prestwich, G. D. Osteochondral defect repair 951
891 with autologous bone marrow-derived mesenchymal stem cells in an 952
892 injectable, in situ, cross-linked synthetic extracellular matrix. *Tissue* 953
893 *Eng.* **2006**, *12* (12), 3405–16.
- 894 (69) Duarte Campos, D. F.; Drescher, W.; Rath, B.; Tingart, M.; 954
895 Fischer, H. Supporting Biomaterials for Articular Cartilage Repair. 955
896 *Cartilage* **2012**, *3* (3), 205–21.
- 897 (70) Cao, Z.; Dou, C.; Dong, S. Scaffolding Biomaterials for Cartilage 956
898 Regeneration. *J. Nanomater.* **2014**, *2014*, 1–8.
- 899 (71) Katayama, R.; Wakitani, S.; Tsumaki, N.; Morita, Y.; Matsushita, 957
900 I.; Gejo, R.; Kimura, T. Repair of articular cartilage defects in rabbits 958
901 using CDMP1 gene-transfected autologous mesenchymal cells derived 959
902 from bone marrow. *Rheumatology (Oxford)* **2004**, *43* (8), 980–5.
- 903 (72) Yokoo, N.; Saito, T.; Uesugi, M.; Kobayashi, N.; Xin, K. Q.; 960
904 Okuda, K.; Mizukami, H.; Ozawa, K.; Koshino, T. Repair of articular 961
905 cartilage defect by autologous transplantation of basic fibroblast 962
906 growth factor gene-transduced chondrocytes with adeno-associated 963
907 virus vector. *Arthritis Rheum.* **2005**, *52* (1), 164–70.
- 908 (73) Kubo, M.; Imai, S.; Fujimiya, M.; Isoya, E.; Ando, K.; Mimura, 964
909 T.; Matsusue, Y. Exogenous collagen-enhanced recruitment of 965
910 mesenchymal stem cells during rabbit articular cartilage repair. *Acta* 966
911 *Orthop.* **2007**, *78* (6), 845–55.
- 912 (74) Mimura, T.; Imai, S.; Okumura, N.; Li, L.; Nishizawa, K.; Araki, 967
913 S.; Ueba, H.; Kubo, M.; Mori, K.; Matsusue, Y. Spatiotemporal control 968
914 of proliferation and differentiation of bone marrow-derived mesen- 969
915 chymal stem cells recruited using collagen hydrogel for repair of 970
916 articular cartilage defects. *J. Biomed. Mater. Res., Part B* **2011**, *98* (2), 971
917 360–8.
- 918 (75) Schneider, U.; Schmidt-Rohlfing, B.; Gavenis, K.; Maus, U.; 972
919 Mueller-Rath, R.; Andereya, S. A comparative study of 3 different 973
920 cartilage repair techniques. *Knee Surg Sports Traumatol Arthrosc* **2011**, 974
921 *19* (12), 2145–52.
- (76) Chen, J.; Wang, F.; Zhang, Y.; Jin, X.; Zhang, L.; Feng, Y.; Lin, 922
X.; Yang, L. In vivo tracking of superparamagnetic iron oxide 923
nanoparticle labeled chondrocytes in large animal model. *Ann. Biomed.* 924
Eng. **2012**, *40* (12), 2568–78. 925
- (77) Igarashi, T.; Iwasaki, N.; Kasahara, Y.; Minami, A. A cellular 926
implantation system using an injectable ultra-purified alginate gel for 927
repair of osteochondral defects in a rabbit model. *J. Biomed. Mater. Res.,* 928
Part A **2010**, *94* (3), 844–855. 929
- (78) Re'em, T.; Witte, F.; Willbold, E.; Ruvinov, E.; Cohen, S. 930
Simultaneous regeneration of articular cartilage and subchondral bone 931
induced by spatially presented TGF-beta and BMP-4 in a bilayer 932
affinity binding system. *Acta Biomater.* **2012**, *8* (9), 3283–93. 933
- (79) Lopiz-Morales, Y.; Abarategi, A.; Ramos, V.; Moreno-Vicente, 934
C.; Lopez-Duran, L.; Lopez-Lacomba, J. L.; Marco, F. In vivo 935
comparison of the effects of rhBMP-2 and rhBMP-4 in osteochondral 936
tissue regeneration. *Eur. Cell Mater.* **2010**, *20*, 367–78.
- (80) Araki, S.; Imai, S.; Ishigaki, H.; Mimura, T.; Nishizawa, K.; Ueba, 938
H.; Kumagai, K.; Kubo, M.; Mori, K.; Ogasawara, K.; Matsusue, Y. 939
Improved quality of cartilage repair by bone marrow mesenchymal 940
stem cells for treatment of an osteochondral defect in a cynomolgus 941
macaque model. *Acta Orthop* **2015**, *86* (1), 119–26. 942
- (81) Dragoo, J. L.; Carlson, G.; McCormick, F.; Khan-Farooqi, H.; 943
Zhu, M.; Zuk, P. A.; Benhaim, P. Healing full-thickness cartilage 944
defects using adipose-derived stem cells. *Tissue Eng.* **2007**, *13* (7), 945
1615–21. 946
- (82) Lee, J. M.; Im, G. I. SOX trio-co-transduced adipose stem cells 947
in fibrin gel to enhance cartilage repair and delay the progression of 948
osteoarthritis in the rat. *Biomaterials* **2012**, *33* (7), 2016–24. 949
- (83) Lee, J. C.; Min, H. J.; Park, H. J.; Lee, S.; Seong, S. C.; Lee, M. 950
C. Synovial membrane-derived mesenchymal stem cells supported by 951
platelet-rich plasma can repair osteochondral defects in a rabbit model. 952
Arthroscopy **2013**, *29* (6), 1034–46. 953
- (84) Kayakabe, M.; Tsutsumi, S.; Watanabe, H.; Kato, Y.; Takagishi, 954
K. Transplantation of autologous rabbit BM-derived mesenchymal 955
stromal cells embedded in hyaluronic acid gel sponge into 956
osteochondral defects of the knee. *Cytotherapy* **2006**, *8* (4), 343–53. 957
- (85) Fisher, M. B.; Belkin, N. S.; Milby, A. H.; Henning, E. A.; 958
Bostrom, M.; Kim, M.; Pfeifer, C.; Meloni, G.; Dodge, G. R.; Burdick, 959
J. A.; Schaer, T. P.; Steinberg, D. R.; Mauck, R. L. Cartilage repair and 960
subchondral bone remodeling in response to focal lesions in a mini-pig 961
model: implications for tissue engineering. *Tissue Eng, Part A* **2015**, *21* 962
(3–4), 850–860. 963
- (86) Oliveira, J. T.; Gardel, L. S.; Rada, T.; Martins, L.; Gomes, M. 964
E.; Reis, R. L. Injectable gellan gum hydrogels with autologous cells for 965
the treatment of rabbit articular cartilage defects. *J. Orthop. Res.* **2010**, 966
28 (9), 1193–9. 967
- (87) Hao, T.; Wen, N.; Cao, J. K.; Wang, H. B.; Lu, S. H.; Liu, T.; 968
Lin, Q. X.; Duan, C. M.; Wang, C. Y. The support of matrix 969
accumulation and the promotion of sheep articular cartilage defects 970
repair in vivo by chitosan hydrogels. *Osteoarthritis Cartilage* **2010**, *18* 971
(2), 257–65. 972
- (88) Albuquerque, P. C.; Aguiar, J. L.; Santos, S. M.; Pontes Filho, 973
N.; Mello, R. J.; Costa, M. L.; Albuquerque, C. M.; Almeida, T. M.; 974
Santos, A. H.; Silva, J. C. Comparative study of the areas of 975
osteochondral defects produced in the femoral condyles of rabbits 976
treated with gel of sugarcane biopolymer. *Acta Cir Bras* **2011**, *26* (5), 977
383–6. 978
- (89) Lim, C. T.; Ren, X.; Afizah, M. H.; Tarigan-Panjaitan, S.; Yang, 979
Z.; Wu, Y.; Chian, K. S.; Mikos, A. G.; Hui, J. H. Repair of 980
osteochondral defects with rehydrated freeze-dried oligo[poly- 981
(ethylene glycol) fumarate] hydrogels seeded with bone marrow 982
mesenchymal stem cells in a porcine model. *Tissue Eng, Part A* **2013**, 983
19 (15–16), 1852–1861. 984
- (90) Park, J. S.; Woo, D. G.; Yang, H. N.; Lim, H. J.; Park, K. M.; Na, 985
K.; Park, K. H. Chondrogenesis of human mesenchymal stem cells 986
encapsulated in a hydrogel construct: neocartilage formation in animal 987
models as both mice and rabbits. *J. Biomed. Mater. Res., Part A* **2010**, 988
92 (3), 988–996. 989

- 990 (91) Jung, Y.; Park, M. S.; Lee, J. W.; Kim, Y. H.; Kim, S. H. Cartilage
991 regeneration with highly-elastic three-dimensional scaffolds prepared
992 from biodegradable poly(L-lactide-co-epsilon-caprolactone). *Biomater-*
993 *ials* **2008**, *29* (35), 4630–4636.
- 994 (92) Dahlin, R. L.; Kinard, L. A.; Lam, J.; Needham, C. J.; Lu, S.;
995 Kasper, F. K.; Mikos, A. G. Articular chondrocytes and mesenchymal
996 stem cells seeded on biodegradable scaffolds for the repair of cartilage
997 in a rat osteochondral defect model. *Biomaterials* **2014**, *35* (26),
998 7460–9.
- 999 (93) Nettles, D. L.; Kitaoka, K.; Hanson, N. A.; Flahiff, C. M.; Mata,
1000 B. A.; Hsu, E. W.; Chilkoti, A.; Setton, L. A. In situ crosslinking elastin-
1001 like polypeptide gels for application to articular cartilage repair in a
1002 goat osteochondral defect model. *Tissue Eng., Part A* **2008**, *14* (7),
1003 1133–1140.
- 1004 (94) Hui, J. H.; Chan, S. W.; Li, J.; Goh, J. C.; Li, L.; Ren, X. F.; Lee,
1005 E. H. Intra-articular delivery of chondroitin sulfate for the treatment of
1006 joint defects in rabbit model. *J. Mol. Histol.* **2007**, *38* (5), 483–9.
- 1007 (95) Dausse, Y.; Grossin, L.; Miralles, G.; Pelletier, S.; Mainard, D.;
1008 Hubert, P.; Baptiste, D.; Gillet, P.; Dellacherie, E.; Netter, P.; Payan, E.
1009 Cartilage repair using new polysaccharidic biomaterials: macroscopic,
1010 histological and biochemical approaches in a rat model of cartilage
1011 defect. *Osteoarthritis Cartilage* **2003**, *11* (1), 16–28.
- 1012 (96) Nishida, T.; Kubota, S.; Kojima, S.; Kuboki, T.; Nakao, K.;
1013 Kushibiki, T.; Tabata, Y.; Takigawa, M. Regeneration of defects in
1014 articular cartilage in rat knee joints by CCN2 (connective tissue
1015 growth factor). *J. Bone Miner. Res.* **2004**, *19* (8), 1308–19.
- 1016 (97) Ishii, I.; Mizuta, H.; Sei, A.; Hirose, J.; Kudo, S.; Hiraki, Y.
1017 Healing of full-thickness defects of the articular cartilage in rabbits
1018 using fibroblast growth factor-2 and a fibrin sealant. *J. Bone Jt. Surg., Br.*
1019 *Vol.* **2007**, *89* (5), 693–700.
- 1020 (98) Park, S. H.; Cui, J. H.; Park, S. R.; Min, B. H. Potential of
1021 fortified fibrin/hyaluronic acid composite gel as a cell delivery vehicle
1022 for chondrocytes. *Artif. Organs* **2009**, *33* (6), 439–47.
- 1023 (99) Lee, J. C.; Lee, S. Y.; Min, H. J.; Han, S. A.; Jang, J.; Lee, S.;
1024 Seong, S. C.; Lee, M. C. Synovium-derived mesenchymal stem cells
1025 encapsulated in a novel injectable gel can repair osteochondral defects
1026 in a rabbit model. *Tissue Eng., Part A* **2012**, *18* (19–20), 2173–2186.
- 1027 (100) Park, J. S.; Yang, H. N.; Woo, D. G.; Jeon, S. Y.; Park, K. H.
1028 Chondrogenesis of human mesenchymal stem cells in fibrin constructs
1029 evaluated in vitro and in nude mouse and rabbit defects models.
1030 *Biomaterials* **2011**, *32* (6), 1495–507.
- 1031 (101) Yasuda, K.; Kitamura, N.; Gong, J. P.; Arakaki, K.; Kwon, H. J.;
1032 Onodera, S.; Chen, Y. M.; Kurokawa, T.; Kanaya, F.; Ohmiya, Y.;
1033 Osada, Y. A novel double-network hydrogel induces spontaneous
1034 articular cartilage regeneration in vivo in a large osteochondral defect.
1035 *Macromol. Biosci.* **2009**, *9* (4), 307–16.
- 1036 (102) Imabuchi, R.; Ohmiya, Y.; Kwon, H. J.; Onodera, S.; Kitamura,
1037 N.; Kurokawa, T.; Gong, J. P.; Yasuda, K. Gene expression profile of
1038 the cartilage tissue spontaneously regenerated in vivo by using a novel
1039 double-network gel: comparisons with the normal articular cartilage.
1040 *BMC Musculoskeletal Disord.* **2011**, *12*, 213.
- 1041 (103) Yokota, M.; Yasuda, K.; Kitamura, N.; Arakaki, K.; Onodera, S.;
1042 Kurokawa, T.; Gong, J. P. Spontaneous hyaline cartilage regeneration
1043 can be induced in an osteochondral defect created in the femoral
1044 condyle using a novel double-network hydrogel. *BMC Musculoskeletal*
1045 *Disord.* **2011**, *12*, 49.
- 1046 (104) Kitamura, N.; Yasuda, K.; Ogawa, M.; Arakaki, K.; Kai, S.;
1047 Onodera, S.; Kurokawa, T.; Gong, J. P. Induction of spontaneous
1048 hyaline cartilage regeneration using a double-network gel: efficacy of a
1049 novel therapeutic strategy for an articular cartilage defect. *Am. J. Sports*
1050 *Med.* **2011**, *39* (6), 1160–9.
- 1051 (105) Ogawa, M.; Kitamura, N.; Kurokawa, T.; Arakaki, K.; Tanaka,
1052 Y.; Gong, J. P.; Yasuda, K. Poly(2-acrylamido-2-methylpropanesulfonic
1053 acid) gel induces articular cartilage regeneration in vivo: comparisons
1054 of the induction ability between single- and double-network gels. *J.*
1055 *Biomed. Mater. Res., Part A* **2012**, *100* (9), 2244–2251.
- 1056 (106) Matsuda, H.; Kitamura, N.; Kurokawa, T.; Arakaki, K.; Gong, J.
1057 P.; Kanaya, F.; Yasuda, K. Influence of the gel thickness on in vivo
1058 hyaline cartilage regeneration induced by double-network gel
implanted at the bottom of a large osteochondral defect: short-term
results. *BMC Musculoskeletal Disord.* **2013**, *14*, 50.
- (107) Degoricija, L.; Bansal, P. N.; Sontjens, S. H.; Joshi, N. S.;
Takahashi, M.; Snyder, B.; Grinstaff, M. W. Hydrogels for
osteochondral repair based on photocrosslinkable carbamate den-
drimers. *Biomacromolecules* **2008**, *9* (10), 2863–72.
- (108) Shokrgozar, M. A.; Bonakdar, S.; Dehghan, M. M.; Emami, S.
H.; Montazeri, L.; Azari, S.; Rabbani, M. Biological evaluation of
polyvinyl alcohol hydrogel crosslinked by polyurethane chain for
cartilage tissue engineering in rabbit model. *J. Mater. Sci.: Mater. Med.*
2013, *24* (10), 2449–2460.
- (109) Fukui, T.; Kitamura, N.; Kurokawa, T.; Yokota, M.; Kondo, E.;
Gong, J. P.; Yasuda, K. Intra-articular administration of hyaluronic acid
increases the volume of the hyaline cartilage regenerated in a large
osteochondral defect by implantation of a double-network gel. *J. Mater.*
Sci.: Mater. Med. **2014**, *25* (4), 1173–82.
- (110) Holland, T. A.; Bodde, E. W.; Baggett, L. S.; Tabata, Y.; Mikos,
A. G.; Jansen, J. A. Osteochondral repair in the rabbit model utilizing
bilayered, degradable oligo(poly(ethylene glycol) fumarate) hydrogel
scaffolds. *J. Biomed. Mater. Res., Part A* **2005**, *75* (1), 156–167.
- (111) Ito, Y.; Ochi, M.; Adachi, N.; Sugawara, K.; Yanada, S.; Ikada,
Y.; Ronakorn, P. Repair of osteochondral defect with tissue-engineered
chondral plug in a rabbit model. *Arthroscopy* **2005**, *21* (10), 1155–63.
- (112) Funayama, A.; Niki, Y.; Matsumoto, H.; Maeno, S.; Yatabe, T.;
Morioka, H.; Yanagimoto, S.; Taguchi, T.; Tanaka, J.; Toyama, Y.
Repair of full-thickness articular cartilage defects using injectable type
II collagen gel embedded with cultured chondrocytes in a rabbit
model. *J. Orthop. Sci.* **2008**, *13* (3), 225–32.
- (113) Lind, M.; Larsen, A.; Clausen, C.; Ooster, K.; Everland, H.
Cartilage repair with chondrocytes in fibrin hydrogel and MPEG
poly lactide scaffold: an in vivo study in goats. *Knee Surg Sports*
Traumatol Arthrosc **2008**, *16* (7), 690–8.
- (114) Lee, C. H.; Cook, J. L.; Mendelson, A.; Moiola, E. K.; Yao, H.;
Mao, J. J. Regeneration of the articular surface of the rabbit synovial
joint by cell homing: a proof of concept study. *Lancet* **2010**, *376*
(9739), 440–8.
- (115) Toh, W. S.; Lee, E. H.; Guo, X. M.; Chan, J. K.; Yeow, C. H.;
Choo, A. B.; Cao, T. Cartilage repair using hyaluronan hydrogel-
encapsulated human embryonic stem cell-derived chondrogenic cells.
Biomaterials **2010**, *31* (27), 6968–80.
- (116) Kim, M.; Kim, S. E.; Kang, S. S.; Kim, Y. H.; Tae, G. The use of
de-differentiated chondrocytes delivered by a heparin-based hydrogel
to regenerate cartilage in partial-thickness defects. *Biomaterials* **2011**,
32 (31), 7883–96.
- (117) Kim, M.; Hong, B.; Lee, J.; Kim, S. E.; Kang, S. S.; Kim, Y. H.;
Tae, G. Composite system of PLCL scaffold and heparin-based
hydrogel for regeneration of partial-thickness cartilage defects.
Biomacromolecules **2012**, *13* (8), 2287–98.
- (118) Lee, H. R.; Park, K. M.; Joung, Y. K.; Park, K. D.; Do, S. H.
Platelet-rich plasma loaded hydrogel scaffold enhances chondrogenic
differentiation and maturation with up-regulation of CB1 and CB2. *J.*
Controlled Release **2012**, *159* (3), 332–7.
- (119) Ohshika, S.; Ishibashi, Y.; Kon, A.; Kusumi, T.; Kijima, H.;
Toh, S. Potential of exogenous cartilage proteoglycan as a new material
for cartilage regeneration. *Int. Orthop* **2012**, *36* (4), 869–77.
- (120) Li, B.; Yang, J.; Ma, L.; Li, F.; Tu, Z.; Gao, C. Fabrication of
poly(lactide-co-glycolide) scaffold filled with fibrin gel, mesenchymal
stem cells, and poly(ethylene oxide)-b-poly(L-lysine)/TGF-beta1
plasmid DNA complexes for cartilage restoration in vivo. *J. Biomed.*
Mater. Res., Part A **2013**, *101* (11), 3097–3108.
- (121) Solchaga, L. A.; Temenoff, J. S.; Gao, J.; Mikos, A. G.; Caplan,
A. I.; Goldberg, V. M. Repair of osteochondral defects with
hyaluronan- and polyester-based scaffolds. *Osteoarthritis Cartilage*
2005, *13* (4), 297–309.
- (122) Frenkel, S. R.; Bradica, G.; Brekke, J. H.; Goldman, S. M.;
Ieska, K.; Issack, P.; Bong, M. R.; Tian, H.; Gokhale, J.; Coutts, R. D.;
Kronengold, R. T. Regeneration of articular cartilage—evaluation of
osteochondral defect repair in the rabbit using multiphasic implants.
Osteoarthritis Cartilage **2005**, *13* (9), 798–807.

- 1128 (123) Vinatier, C.; Gauthier, O.; Fatimi, A.; Merceron, C.; Masson,
1129 M.; Moreau, A.; Moreau, F.; Fellah, B.; Weiss, P.; Guicheux, J. An
1130 injectable cellulose-based hydrogel for the transfer of autologous nasal
1131 chondrocytes in articular cartilage defects. *Biotechnol. Bioeng.* **2009**, *102*
1132 (4), 1259–67.
- 1133 (124) Lam, J.; Lu, S.; Lee, E. J.; Trachtenberg, J. E.; Meretoja, V. V.;
1134 Dahlin, R. L.; van den Beucken, J. J.; Tabata, Y.; Wong, M. E.; Jansen,
1135 J. A.; Mikos, A. G.; Kasper, F. K. Osteochondral defect repair using
1136 bilayered hydrogels encapsulating both chondrogenically and
1137 osteogenically pre-differentiated mesenchymal stem cells in a rabbit
1138 model. *Osteoarthritis Cartilage* **2014**, *22* (9), 1291–300.
- 1139 (125) Wang, W.; Sun, L.; Zhang, P.; Song, J.; Liu, W. An anti-
1140 inflammatory cell-free collagen/resveratrol scaffold for repairing
1141 osteochondral defects in rabbits. *Acta Biomater.* **2014**, *10* (12),
1142 4983–95.
- 1143 (126) Lu, S.; Lam, J.; Trachtenberg, J. E.; Lee, E. J.; Seyednejad, H.;
1144 van den Beucken, J. J.; Tabata, Y.; Wong, M. E.; Jansen, J. A.; Mikos, A.
1145 G.; Kasper, F. K. Dual growth factor delivery from bilayered,
1146 biodegradable hydrogel composites for spatially-guided osteochondral
1147 tissue repair. *Biomaterials* **2014**, *35* (31), 8829–39.
- 1148 (127) Needham, C. J.; Shah, S. R.; Dahlin, R. L.; Kinard, L. A.; Lam,
1149 J.; Watson, B. M.; Lu, S.; Kasper, F. K.; Mikos, A. G. Osteochondral
1150 tissue regeneration through polymeric delivery of DNA encoding for
1151 the SOX trio and RUNX2. *Acta Biomater.* **2014**, *10* (10), 4103–12.
- 1152 (128) Han, F.; Yang, X.; Zhao, J.; Zhao, Y.; Yuan, X. Photo-
1153 crosslinked layered gelatin-chitosan hydrogel with graded composi-
1154 tions for osteochondral defect repair. *J. Mater. Sci.: Mater. Med.* **2015**,
1155 *26* (4), 160.
- 1156 (129) Mazaki, T.; Shiozaki, Y.; Yamane, K.; Yoshida, A.; Nakamura,
1157 M.; Yoshida, Y.; Zhou, D.; Kitajima, T.; Tanaka, M.; Ito, Y.; Ozaki, T.;
1158 Matsukawa, A. A novel, visible light-induced, rapidly cross-linkable
1159 gelatin scaffold for osteochondral tissue engineering. *Sci. Rep.* **2014**, *4*,
1160 4457.
- 1161 (130) Leone, G.; Fini, M.; Torricelli, P.; Giardino, R.; Barbucci, R. An
1162 amidated carboxymethylcellulose hydrogel for cartilage regeneration. *J.*
1163 *Mater. Sci.: Mater. Med.* **2008**, *19* (8), 2873–80.
- 1164 (131) Bal, B. S.; Rahaman, M. N.; Jayabalan, P.; Kuroki, K.; Cockrell,
1165 M. K.; Yao, J. Q.; Cook, J. L. In vivo outcomes of tissue-engineered
1166 osteochondral grafts. *J. Biomed. Mater. Res., Part B* **2010**, *93* (1), 164–
1167 174.
- 1168 (132) Zhang, W.; Lian, Q.; Li, D.; Wang, K.; Hao, D.; Bian, W.; He,
1169 J.; Jin, Z. Cartilage repair and subchondral bone migration using 3D
1170 printing osteochondral composites: a one-year-period study in rabbit
1171 trochlea. *BioMed Res. Int.* **2014**, *2014*, 746138.
- 1172 (133) Ge, Z.; Li, C.; Heng, B. C.; Cao, G.; Yang, Z. Functional
1173 biomaterials for cartilage regeneration. *J. Biomed. Mater. Res., Part A*
1174 **2012**, *100* (9), 2526–2536.
- 1175 (134) Toh, W. S.; Spector, M.; Lee, E. H.; Cao, T. Biomaterial-
1176 mediated delivery of microenvironmental cues for repair and
1177 regeneration of articular cartilage. *Mol. Pharmaceutics* **2011**, *8* (4),
1178 994–1001.
- 1179 (135) Chu, C. R.; Szczodry, M.; Bruno, S. Animal models for
1180 cartilage regeneration and repair. *Tissue Eng., Part B* **2010**, *16* (1),
1181 105–115.
- 1182 (136) Rasanen, T.; Messner, K. Regional variations of indentation
1183 stiffness and thickness of normal rabbit knee articular cartilage. *J.*
1184 *Biomed. Mater. Res.* **1996**, *31* (4), 519–524.
- 1185 (137) Ahern, B. J.; Parvizi, J.; Boston, R.; Schaer, T. P. Preclinical
1186 animal models in single site cartilage defect testing: a systematic
1187 review. *Osteoarthritis Cartilage* **2009**, *17* (6), 705–13.
- 1188 (138) Aigner, T.; Cook, J. L.; Gerwin, N.; Glasson, S. S.; Laverty, S.;
1189 Little, C. B.; McIlwraith, W.; Kraus, V. B. Histopathology atlas of
1190 animal model systems - overview of guiding principles. *Osteoarthritis*
1191 *Cartilage* **2010**, *18* (Suppl 3), S2–S6.
- 1192 (139) Shapiro, F.; Koide, S.; Glimcher, M. J. Cell origin and
1193 differentiation in the repair of full-thickness defects of articular
1194 cartilage. *J. Bone Joint Surg Am.* **1993**, *75* (4), 532–553.
- (140) Koch, T. G.; Betts, D. H. Stem cell therapy for joint problems
1195 using the horse as a clinically relevant animal model. *Expert Opin. Biol.*
1196 *Ther.* **2007**, *7* (11), 1621–6.
- (141) Convery, F. R.; Akeson, W. H.; Keown, G. H. The repair of
1198 large osteochondral defects. An experimental study in horses. *Clin.*
1199 *Orthop. Relat. Res.* **1972**, *82*, 253–262.
- (142) Shortkroff, S.; Barone, L.; Hsu, H. P.; Wrenn, C.; Gagne, T.;
1201 Chi, T.; Breinan, H.; Minas, T.; Sledge, C. B.; Tubo, R.; Spector, M.
1202 Healing of chondral and osteochondral defects in a canine model: the
1203 role of cultured chondrocytes in regeneration of articular cartilage.
1204 *Biomaterials* **1996**, *17* (2), 147–154.
- (143) Lu, Y.; Markel, M. D.; Swain, C.; Kaplan, L. D. Development
1206 of partial thickness articular cartilage injury in an ovine model. *J.*
1207 *Orthop. Res.* **2006**, *24* (10), 1974–82.
- (144) Frisbie, D. D.; Cross, M. W.; McIlwraith, C. W. A comparative
1209 study of articular cartilage thickness in the stifle of animal species used
1210 in human pre-clinical studies compared to articular cartilage thickness
1211 in the human knee. *Vet. Comp. Orthop. Traumatol.* **2006**, *19* (3), 142–
1212 146.
- (145) Hepp, P.; Osterhoff, G.; Niederhagen, M.; Marquass, B.;
1214 Aigner, T.; Bader, A.; Josten, C.; Schulz, R. Perilesional changes of
1215 focal osteochondral defects in an ovine model and their relevance to
1216 human osteochondral injuries. *J. Bone Jt. Surg., Br. Vol.* **2009**, *91* (8),
1217 1110–1119.
- (146) Kim, H. K.; Moran, M. E.; Salter, R. B. The potential for
1219 regeneration of articular cartilage in defects created by chondral
1220 shaving and subchondral abrasion. An experimental investigation in
1221 rabbits. *J. Bone Joint Surg Am.* **1991**, *73* (9), 1301–1315.
- (147) Bonasia, D. E.; Marmotti, A.; Massa, A. D.; Ferro, A.; Blonna,
1223 D.; Castoldi, F.; Rossi, R. Intra- and inter-observer reliability of ten
1224 major histological scoring systems used for the evaluation of in vivo
1225 cartilage repair. *Knee Surg. Sports Traumatol. Arthrosc.* **2014**,
1226 DOI: 10.1007/s00167-014-2975-8.
- (148) Rutgers, M.; van Pelt, M. J.; Dhert, W. J.; Creemers, L. B.;
1228 Saris, D. B. Evaluation of histological scoring systems for tissue-
1229 engineered, repaired and osteoarthritic cartilage. *Osteoarthritis*
1230 *Cartilage* **2010**, *18* (1), 12–23.
- (149) Orth, P.; Zurakowski, D.; Wincheringer, D.; Madry, H.
1232 Reliability, Reproducibility, and Validation of Five Major Histological
1233 Scoring Systems for Experimental Articular Cartilage Repair in the
1234 Rabbit Model. *Tissue Eng., Part C* **2012**, *18* (5), 329–339.
- (150) Hurtig, M. B.; Buschmann, M. D.; Fortier, L. A.; Caroline D.
1236 Hoemann Ernest B. Hunziker; Jurvelin, J. S.; Mainil-Varlet, P.;
1237 McIlwraith, C. W.; Sah, R. L.; Whiteside, R. A., Preclinical Studies for
1238 Cartilage Repair: Recommendations from International Cartilage
1239 Repair Society. *Cartilage* **2011**, *2* (2), 137–152, DOI:10.1177/
1240 1947603511401905
- (151) *Standard Guide for in Vivo Assessment of Implantable Devices*
1242 *Intended to Repair or Regenerate Articular Cartilage*; ASTM F2451-05 ;
1243 ASTM International: West Conshohocken, NJ, 2010.